Rida Shakeel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Rida Shakeel has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Sohaib Aftab Ahmad Chaudhry
ABWA Medical College Faisalabad Pakistan
5 shared publications - Alishba Fatima
Dow University of Health Sciences, Karachi, Pakistan
4 shared publications - Muhammad Hasnain Azeem
Dow University of Health Sciences, Karachi, Pakistan
4 shared publications - Danish Hassan
Dow Medical College, DUHS, Karachi, Pakistan
3 shared publications - Emad Uddin Sajid
Department of Medicine Dow University of Health Sciences Karachi Pakistan
3 shared publications - Syed Rayyan Ahmed
Department of Medicine Dow University of Health Sciences Karachi Pakistan
3 shared publications
Latest Publications
- 9 September 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
Clinical Outcomes of Conduction System versus Right Ventricular Pacing after TAVR: A Systematic Review and Meta‐Analysis
Background: Permanent pacemaker implantation is required in up to 25% of patients after transcatheter aortic valve replacement (TAVR). Conventional right ventricular pacing (RVP) may promote dyssynchrony, whereas conduction system pacing (CSP) preserves physiological activation. Research Question: Does CSP improve clinical, echocardiographic, electrical, and procedural outcomes compared with RVP in patients requiring pacing after TAVR? Methods: We conducted a PROSPERO‐registered systematic review and meta‐analysis following PRISMA 2020. PubMed, Embase, Scopus, and ClinicalTrials.gov were searched through June 2026 for randomized and comparative observational studies of CSP versus RVP after TAVR. Random‐effects models generated risk ratios (RRs) or mean differences (MDs) with 95% confidence intervals (CIs). Prediction intervals, cumulative meta‐analysis, leave‐one‐out analyses, and GRADE assessment were performed. Results: Six studies, one randomized trial and five observational studies, enrolled 675 patients (CSP, n = 344; RVP, n = 331). CSP was associated with fewer heart‐failure hospitalizations (RR 0.49, 95% CI 0.29–0.83; p = 0.017; I 2 = 5%) and shorter paced QRS duration (MD −31.05 ms, 95% CI −34.07 to −28.02; p < 0.001; I 2 = 0%). All‐cause mortality, cardiovascular death, and change in left ventricular ejection fraction did not differ significantly. Implantation success was modestly lower with CSP (RR 0.91; p = 0.014). Conclusion: CSP was associated with fewer heart‐failure hospitalizations and shorter paced QRS duration than RVP after TAVR. Evidence was predominantly observational, and no significant differences were demonstrated in mortality or change in left ventricular ejection fraction. The potential clinical relevance of CSP when a high ventricular pacing burden is anticipated remains plausible but was not directly demonstrated by the available data; adequately powered randomized trials are required before routine adoption.
- 9 September 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
Clinical Outcomes of Conduction System versus Right Ventricular Pacing after TAVR: A Systematic Review and Meta‐Analysis
Background: Permanent pacemaker implantation is required in up to 25% of patients after transcatheter aortic valve replacement (TAVR). Conventional right ventricular pacing (RVP) may promote dyssynchrony, whereas conduction system pacing (CSP) preserves physiological activation. Research Question: Does CSP improve clinical, echocardiographic, electrical, and procedural outcomes compared with RVP in patients requiring pacing after TAVR? Methods: We conducted a PROSPERO‐registered systematic review and meta‐analysis following PRISMA 2020. PubMed, Embase, Scopus, and ClinicalTrials.gov were searched through June 2026 for randomized and comparative observational studies of CSP versus RVP after TAVR. Random‐effects models generated risk ratios (RRs) or mean differences (MDs) with 95% confidence intervals (CIs). Prediction intervals, cumulative meta‐analysis, leave‐one‐out analyses, and GRADE assessment were performed. Results: Six studies, one randomized trial and five observational studies, enrolled 675 patients (CSP, n = 344; RVP, n = 331). CSP was associated with fewer heart‐failure hospitalizations (RR 0.49, 95% CI 0.29–0.83; p = 0.017; I 2 = 5%) and shorter paced QRS duration (MD −31.05 ms, 95% CI −34.07 to −28.02; p < 0.001; I 2 = 0%). All‐cause mortality, cardiovascular death, and change in left ventricular ejection fraction did not differ significantly. Implantation success was modestly lower with CSP (RR 0.91; p = 0.014). Conclusion: CSP was associated with fewer heart‐failure hospitalizations and shorter paced QRS duration than RVP after TAVR. Evidence was predominantly observational, and no significant differences were demonstrated in mortality or change in left ventricular ejection fraction. The potential clinical relevance of CSP when a high ventricular pacing burden is anticipated remains plausible but was not directly demonstrated by the available data; adequately powered randomized trials are required before routine adoption.
- Open Access
- 15 June 2026
- Published by Wiley in Clinical Cardiology
- Vol. 49 (6) , e70369
Moderate Intensity Statins Plus Ezetimibe Combination Therapy Versus High Intensity Statins Monotherapy After Percutaneous Coronary Intervention: A Systematic Review and Meta‐Analysis
Background: High‐intensity statins are standard therapy after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS), yet tolerability concerns and residual cardiovascular risk remain important challenges. Moderate‐intensity statin therapy combined with ezetimibe has emerged as a potential alternative, although its comparative effectiveness after PCI remains uncertain. Methods: We performed a systematic review and meta‐analysis according to PRISMA guidelines. PubMed, Cochrane Library, and ClinicalTrials.gov were searched through September 2025 for studies enrolling adults undergoing PCI and comparing moderate‐intensity statin plus ezetimibe therapy with high‐intensity statin therapy. The primary outcome was major adverse cardiovascular events (MACE), defined as all‐cause mortality, myocardial infarction (MI), stroke, and revascularization. Secondary outcomes included individual cardiovascular endpoints and safety outcomes such as new‐onset diabetes and rhabdomyolysis. Random‐effects models were used to calculate pooled risk ratios (RRs). Results: Nine studies involving 179 621 patients were included, the majority being observational studies. No significant difference was observed in MACE between treatment strategies (RR 0.96, 95% CI 0.81–1.12). Modest reductions were observed in cardiovascular mortality (RR 0.83, 95% CI 0.71–0.98) and MI (RR 0.74, 95% CI 0.58–0.95), although findings were non‐robust with wide prediction intervals. Revascularization rates were similar between groups. Subgroup analyses suggested lower heterogeneity in intermediate follow‐up and non‐ACS populations. Conclusions: Moderate‐intensity statin plus ezetimibe therapy may provide cardiovascular outcomes comparable to high‐intensity statins after PCI. However, persistent heterogeneity limits certainty, and large randomized trials are needed to confirm long‐term efficacy and safety.
- 15 June 2026
- Published by Wiley in Clinical Cardiology
- Vol. 49 (6) , e70369
Open AccessModerate Intensity Statins Plus Ezetimibe Combination Therapy Versus High Intensity Statins Monotherapy After Percutaneous Coronary Intervention: A Systematic Review and Meta‐Analysis
Background: High‐intensity statins are standard therapy after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS), yet tolerability concerns and residual cardiovascular risk remain important challenges. Moderate‐intensity statin therapy combined with ezetimibe has emerged as a potential alternative, although its comparative effectiveness after PCI remains uncertain. Methods: We performed a systematic review and meta‐analysis according to PRISMA guidelines. PubMed, Cochrane Library, and ClinicalTrials.gov were searched through September 2025 for studies enrolling adults undergoing PCI and comparing moderate‐intensity statin plus ezetimibe therapy with high‐intensity statin therapy. The primary outcome was major adverse cardiovascular events (MACE), defined as all‐cause mortality, myocardial infarction (MI), stroke, and revascularization. Secondary outcomes included individual cardiovascular endpoints and safety outcomes such as new‐onset diabetes and rhabdomyolysis. Random‐effects models were used to calculate pooled risk ratios (RRs). Results: Nine studies involving 179 621 patients were included, the majority being observational studies. No significant difference was observed in MACE between treatment strategies (RR 0.96, 95% CI 0.81–1.12). Modest reductions were observed in cardiovascular mortality (RR 0.83, 95% CI 0.71–0.98) and MI (RR 0.74, 95% CI 0.58–0.95), although findings were non‐robust with wide prediction intervals. Revascularization rates were similar between groups. Subgroup analyses suggested lower heterogeneity in intermediate follow‐up and non‐ACS populations. Conclusions: Moderate‐intensity statin plus ezetimibe therapy may provide cardiovascular outcomes comparable to high‐intensity statins after PCI. However, persistent heterogeneity limits certainty, and large randomized trials are needed to confirm long‐term efficacy and safety.
- 8 May 2026
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 111, 107222
Multimodal benefits of VR-based treadmill training in multiple sclerosis: A systematic review
- 8 May 2026
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 111, 107222
Multimodal benefits of VR-based treadmill training in multiple sclerosis: A systematic review
- Open Access
- 7 May 2026
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 21 (1)
Transcatheter edge-to-edge repair and left ventricular assist devices for secondary mitral regurgitation in advanced heart failure: a scoping review
Background: Secondary mitral regurgitation (SMR) worsens outcomes in advanced heart failure. Transcatheter edge-to-edge repair (TEER) and left ventricular assist device (LVAD) implantation represent advanced treatment options for patients with persistent symptoms despite guideline-directed medical therapy (GDMT). Methods: A scoping review using a PICO framework identified contemporary studies published up to 2025 involving adults with advanced heart failure (NYHA III–IV, INTERMACS 1–7) and ≥moderate SMR. Outcomes included mortality, heart failure hospitalizations, functional status, mitral regurgitation reduction, ventricular remodeling, complications, and quality of life. Results: Nine studies including over 2,000 patients were analyzed (mean age 60–72 years; LVEF 15–33%). TEER was associated with lower mortality and fewer heart failure hospitalizations compared with GDMT in selected patients. LVAD recipients generally had more advanced disease (predominantly INTERMACS 1–3) with higher early mortality but substantial functional improvement. TEER achieved MR ≤ 2 + in 84–99% of patients with low procedural complication rates (1–9%), whereas LVAD therapy demonstrated greater functional improvement but higher device-related complications. Conclusion: TEER is associated with improved outcomes in selected patients with advanced heart failure and SMR, while LVAD therapy remains essential for patients with end-stage disease requiring durable circulatory support.
- 7 May 2026
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 21 (1)
Open AccessTranscatheter edge-to-edge repair and left ventricular assist devices for secondary mitral regurgitation in advanced heart failure: a scoping review
Background: Secondary mitral regurgitation (SMR) worsens outcomes in advanced heart failure. Transcatheter edge-to-edge repair (TEER) and left ventricular assist device (LVAD) implantation represent advanced treatment options for patients with persistent symptoms despite guideline-directed medical therapy (GDMT). Methods: A scoping review using a PICO framework identified contemporary studies published up to 2025 involving adults with advanced heart failure (NYHA III–IV, INTERMACS 1–7) and ≥moderate SMR. Outcomes included mortality, heart failure hospitalizations, functional status, mitral regurgitation reduction, ventricular remodeling, complications, and quality of life. Results: Nine studies including over 2,000 patients were analyzed (mean age 60–72 years; LVEF 15–33%). TEER was associated with lower mortality and fewer heart failure hospitalizations compared with GDMT in selected patients. LVAD recipients generally had more advanced disease (predominantly INTERMACS 1–3) with higher early mortality but substantial functional improvement. TEER achieved MR ≤ 2 + in 84–99% of patients with low procedural complication rates (1–9%), whereas LVAD therapy demonstrated greater functional improvement but higher device-related complications. Conclusion: TEER is associated with improved outcomes in selected patients with advanced heart failure and SMR, while LVAD therapy remains essential for patients with end-stage disease requiring durable circulatory support.
- Open Access
- 13 June 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (7) , 4356-4361
The relation between C-reactive protein (CRP) and risk of incident heart failure in patients with cardiovascular disease: a narrative review
Cardiovascular disease (CVD) remains a leading global cause of morbidity and mortality, with heart failure (HF) significantly contributing to this burden. Elevated C-reactive protein (CRP), a biomarker of systemic inflammation, has been implicated in the pathogenesis of various cardiovascular conditions, including HF. This narrative review examines the relationship between CRP levels and the risk of incident HF in patients with pre-existing CVD. By synthesizing findings from prospective cohort studies, clinical trials, and meta-analyses, we aim to assess the potential role of CRP as a predictive biomarker for HF onset. Inflammation is a critical component in HF pathophysiology, contributing to myocardial remodeling, fibrosis, and endothelial dysfunction. High-sensitivity CRP (hs-CRP) assays allow for the detection of low-grade inflammation, offering improved risk stratification for cardiovascular events. Studies indicate that elevated hs-CRP levels correlate with an increased risk of myocardial infarction, stroke, and HF development. However, CRP’s specificity as a marker remains a challenge due to its association with various systemic inflammatory conditions. Recent research has explored CRP’s role in HF subtypes, particularly HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF). Despite growing evidence linking CRP to HF, gaps remain in understanding its mechanistic role, optimal clinical thresholds, and therapeutic implications. Future research should focus on mechanistic studies elucidating CRP’s direct impact on myocardial dysfunction, subgroup-specific analyses, and interventional trials targeting CRP-driven inflammation. Addressing these gaps could significantly improve HF prevention and management by leveraging CRP as a viable prognostic and therapeutic target.
- 13 June 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (7) , 4356-4361
Open AccessThe relation between C-reactive protein (CRP) and risk of incident heart failure in patients with cardiovascular disease: a narrative review
Cardiovascular disease (CVD) remains a leading global cause of morbidity and mortality, with heart failure (HF) significantly contributing to this burden. Elevated C-reactive protein (CRP), a biomarker of systemic inflammation, has been implicated in the pathogenesis of various cardiovascular conditions, including HF. This narrative review examines the relationship between CRP levels and the risk of incident HF in patients with pre-existing CVD. By synthesizing findings from prospective cohort studies, clinical trials, and meta-analyses, we aim to assess the potential role of CRP as a predictive biomarker for HF onset. Inflammation is a critical component in HF pathophysiology, contributing to myocardial remodeling, fibrosis, and endothelial dysfunction. High-sensitivity CRP (hs-CRP) assays allow for the detection of low-grade inflammation, offering improved risk stratification for cardiovascular events. Studies indicate that elevated hs-CRP levels correlate with an increased risk of myocardial infarction, stroke, and HF development. However, CRP’s specificity as a marker remains a challenge due to its association with various systemic inflammatory conditions. Recent research has explored CRP’s role in HF subtypes, particularly HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF). Despite growing evidence linking CRP to HF, gaps remain in understanding its mechanistic role, optimal clinical thresholds, and therapeutic implications. Future research should focus on mechanistic studies elucidating CRP’s direct impact on myocardial dysfunction, subgroup-specific analyses, and interventional trials targeting CRP-driven inflammation. Addressing these gaps could significantly improve HF prevention and management by leveraging CRP as a viable prognostic and therapeutic target.
- Open Access
- 25 March 2025
- Published by Innovacore Center for Research & Biotech in INNOVAPATH
- Vol. 1 (1) , 9
Immunosuppression in Transplantation: Balancing Efficacy and Long-Term Outcomes
Background: Immunosuppressive therapy is critical for preventing graft rejection in transplant recipients, but long-term use is associated with significant complications, including infections and malignancies. Objectives: This narrative review evaluates the evolution of immunosuppressive strategies in transplantation, focusing on achieving a balance between efficacy and long-term patient safety. Methods: We reviewed clinical trials and observational studies from 2012 to 2024, focusing on calcineurin inhibitors, mTOR inhibitors, and novel biologics in renal and liver transplantation. Results: Modern protocols combining tacrolimus with mycophenolate mofetil have reduced acute rejection rates to below 10%. However, long-term use increases the risk of nephrotoxicity and infections by 25%. Emerging biologics, such as belatacept, show promise in reducing these risks but are limited by high costs and variable efficacy in high-risk patients. Conclusion: Tailored immunosuppression regimens that minimize toxicity while preventing rejection are essential for improving long-term outcomes. Future research should focus on personalized medicine approaches and the development of cost-effective biologics.
- 25 March 2025
- Published by Innovacore Center for Research & Biotech in INNOVAPATH
- Vol. 1 (1) , 9
Open AccessImmunosuppression in Transplantation: Balancing Efficacy and Long-Term Outcomes
Background: Immunosuppressive therapy is critical for preventing graft rejection in transplant recipients, but long-term use is associated with significant complications, including infections and malignancies. Objectives: This narrative review evaluates the evolution of immunosuppressive strategies in transplantation, focusing on achieving a balance between efficacy and long-term patient safety. Methods: We reviewed clinical trials and observational studies from 2012 to 2024, focusing on calcineurin inhibitors, mTOR inhibitors, and novel biologics in renal and liver transplantation. Results: Modern protocols combining tacrolimus with mycophenolate mofetil have reduced acute rejection rates to below 10%. However, long-term use increases the risk of nephrotoxicity and infections by 25%. Emerging biologics, such as belatacept, show promise in reducing these risks but are limited by high costs and variable efficacy in high-risk patients. Conclusion: Tailored immunosuppression regimens that minimize toxicity while preventing rejection are essential for improving long-term outcomes. Future research should focus on personalized medicine approaches and the development of cost-effective biologics.
- Open Access
- 25 March 2025
- Published by Innovacore Center for Research & Biotech in INNOVAPATH
- Vol. 1 (1) , 7
A Sustainable Model for Renal Transplantation in Low-Resource Settings: The SIUT Experience
Background: Pakistan, with a population of over 240 million, has an estimated end-stage renal disease (ESRD) incidence of 100 per million, yet only 10% of patients access renal replacement therapy due to cost and resource limitations. The Sindh Institute of Urology and Transplantation (SIUT) has pioneered a free, community-supported renal transplantation model since the 1980s. Objectives: This narrative review examines the SIUT model as a sustainable approach to renal transplantation in low-resource settings, highlighting its scalability. Methods: We reviewed operational data, patient outcomes, and funding mechanisms from SIUT’s records (1986–2024), supplemented by comparative analyses with other low-income country models. Results: SIUT has performed over 6,000 renal transplants, with a 90% graft survival rate at one year, funded through a 40-60% government-community partnership. Challenges include reliance on living donors (95% of cases) and limited deceased donor programs. The model’s annual budget of $28 million (2010) has remained sustainable through local philanthropy, reducing patient costs to zero. Conclusion: The SIUT model demonstrates that free, integrated dialysis and transplant services are feasible in low-resource settings with strong community support. Future research should explore integrating deceased donation to enhance scalability. Keywords: Renal transplantation, Low-resource settings, SIUT, Pakistan, sustainability
- 25 March 2025
- Published by Innovacore Center for Research & Biotech in INNOVAPATH
- Vol. 1 (1) , 7
Open AccessA Sustainable Model for Renal Transplantation in Low-Resource Settings: The SIUT Experience
Background: Pakistan, with a population of over 240 million, has an estimated end-stage renal disease (ESRD) incidence of 100 per million, yet only 10% of patients access renal replacement therapy due to cost and resource limitations. The Sindh Institute of Urology and Transplantation (SIUT) has pioneered a free, community-supported renal transplantation model since the 1980s. Objectives: This narrative review examines the SIUT model as a sustainable approach to renal transplantation in low-resource settings, highlighting its scalability. Methods: We reviewed operational data, patient outcomes, and funding mechanisms from SIUT’s records (1986–2024), supplemented by comparative analyses with other low-income country models. Results: SIUT has performed over 6,000 renal transplants, with a 90% graft survival rate at one year, funded through a 40-60% government-community partnership. Challenges include reliance on living donors (95% of cases) and limited deceased donor programs. The model’s annual budget of $28 million (2010) has remained sustainable through local philanthropy, reducing patient costs to zero. Conclusion: The SIUT model demonstrates that free, integrated dialysis and transplant services are feasible in low-resource settings with strong community support. Future research should explore integrating deceased donation to enhance scalability. Keywords: Renal transplantation, Low-resource settings, SIUT, Pakistan, sustainability
- Open Access
- 25 March 2025
- Published by Innovacore Center for Research & Biotech in INNOVAPATH
- Vol. 1 (1) , 7
Addressing Rural-Urban Disparities in Access to Renal Transplantation in Pakistan: A Narrative Review
Background: Pakistan’s healthcare system is marked by stark rural-urban disparities, with 62% of the population residing in rural areas but only 20% of transplant facilities located outside major cities like Karachi and Lahore. This inequity exacerbates the burden of end-stage renal disease (ESRD) for rural patients, who often cannot afford travel or treatment costs. Objective: This narrative review assesses rural-urban disparities in access to renal transplantation in Pakistan and explores strategies to improve equity in transplant care. Methods: We analyzed hospital data, patient registries, and policy reports from 2015 to 2024, focusing on transplant outcomes and access challenges in rural Punjab, Sindh, and Khyber Pakhtunkhwa. We also reviewed mobile health initiatives and public-private partnership models. Results: Rural patients face a 40% lower likelihood of receiving a transplant compared to urban patients, primarily due to transportation barriers and lack of local dialysis centers. Only 5% of rural ESRD patients are referred to transplant centers annually. Initiatives like SIUT’s mobile dialysis units have reached 10,000 rural patients since 2018, but transplant follow-up remains challenging due to limited local expertise. Conclusion: Bridging rural-urban disparities requires decentralized transplant care, mobile health units, and training for rural healthcare providers. Future research should focus on cost-effective models to expand transplant services to underserved regions.
- 25 March 2025
- Published by Innovacore Center for Research & Biotech in INNOVAPATH
- Vol. 1 (1) , 7
Open AccessAddressing Rural-Urban Disparities in Access to Renal Transplantation in Pakistan: A Narrative Review
Background: Pakistan’s healthcare system is marked by stark rural-urban disparities, with 62% of the population residing in rural areas but only 20% of transplant facilities located outside major cities like Karachi and Lahore. This inequity exacerbates the burden of end-stage renal disease (ESRD) for rural patients, who often cannot afford travel or treatment costs. Objective: This narrative review assesses rural-urban disparities in access to renal transplantation in Pakistan and explores strategies to improve equity in transplant care. Methods: We analyzed hospital data, patient registries, and policy reports from 2015 to 2024, focusing on transplant outcomes and access challenges in rural Punjab, Sindh, and Khyber Pakhtunkhwa. We also reviewed mobile health initiatives and public-private partnership models. Results: Rural patients face a 40% lower likelihood of receiving a transplant compared to urban patients, primarily due to transportation barriers and lack of local dialysis centers. Only 5% of rural ESRD patients are referred to transplant centers annually. Initiatives like SIUT’s mobile dialysis units have reached 10,000 rural patients since 2018, but transplant follow-up remains challenging due to limited local expertise. Conclusion: Bridging rural-urban disparities requires decentralized transplant care, mobile health units, and training for rural healthcare providers. Future research should focus on cost-effective models to expand transplant services to underserved regions.